No Data
Biodesix Named to Inc. Magazine's 2024 "Best Workplaces"
Awarding Excellence in Company Culture Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, is honored to announce it has been named to Inc. Magazine's Best Workplaces list. The ranking is a result of
Biodesix to Participate in Two Investor Conferences in June
Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer, will participate in two upcoming investor conferences: William
Biodesix to Present New Data on the Nodify XL2 Test at ATS 2024 Annual Meeting
Data highlights ability of the Nodify XL2 test to identify benign nodules in patients with emphysema.
Biodesix Initiated at Buy by TD Cowen
Biodesix Initiated at Buy by TD Cowen
Biodesix (BDSX.US) was first covered by TD Cowen, which gave it a buy rating, with a target price of $2.80.
Biodesix (BDSX.US) was first covered by TD Cowen, which gave it a buy rating, with a target price of $2.80.
Biodesix Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/13/2024 68.67% TD Cowen → $2.8 Initiates Coverage On → Buy 05/03/2024 80.72% Lake Street → $3 Initiates